Overview
A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from glycine or threonine. It is involved in the biosynthesis of purines; pyrimidines; and other amino acids.
Indication
Used as a natural moisturizing agent in some cosmetics and skin care products.
Associated Conditions
- Iron Deficiency Anemia (IDA)
- Iron Deficiency (ID)
Research Report
A Comprehensive Monograph on Serine (DB00133): From Core Metabolism to Therapeutic Frontiers
Executive Summary
Serine is a proteinogenic α-amino acid that occupies a position of profound significance in human biochemistry and pharmacology. Traditionally classified as a nutritionally non-essential amino acid due to the body's capacity for endogenous synthesis, a more nuanced understanding now recognizes it as "conditionally essential." This revised status reflects the reality that endogenous production is often insufficient to meet the metabolic demands imposed by various physiological states, such as rapid growth and development, or pathological conditions, including certain genetic and neurodegenerative disorders. With the DrugBank identifier DB00133 and CAS Number 56-45-1, this small molecule is far more than a simple structural component; it is a central hub of intermediary metabolism.
The metabolic indispensability of L-serine, the naturally occurring stereoisomer, stems primarily from its role as the principal donor of one-carbon units to the folate cycle. This function establishes a direct and critical biochemical link between central carbon metabolism (glycolysis) and the de novo synthesis of essential biomolecules, including purines and pyrimidines, the building blocks of DNA and RNA. Consequently, serine metabolism is intrinsically tied to cellular proliferation, growth, and repair. Furthermore, L-serine serves as a key precursor for the synthesis of other amino acids, such as glycine and cysteine, and is a foundational component of critical lipids, including phospholipids and sphingolipids, which are vital for the structural integrity and function of all cell membranes, particularly within the central nervous system (CNS).
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2023/11/02 | Phase 2 | Recruiting | |||
2019/09/18 | Phase 4 | Active, not recruiting | |||
2019/07/09 | Phase 3 | Withdrawn | |||
2019/06/20 | Phase 4 | Terminated | |||
2018/07/09 | Phase 2 | Terminated | Elijah W. Stommel | ||
2017/02/23 | Phase 2 | Terminated | Aleksandra Stark | ||
2013/04/19 | Phase 1 | UNKNOWN | |||
2012/11/27 | Phase 1 | Completed | |||
2010/09/21 | Phase 3 | Terminated | Clinical Evaluation Research Unit at Kingston General Hospital | ||
2007/07/11 | Phase 2 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Baxter Healthcare Corporation | 0338-0184 | INTRAVENOUS | 400 mg in 100 mL | 4/13/2021 | |
Baxter Healthcare Company | 0338-0210 | INTRAVENOUS | 400 mg in 100 mL | 9/21/2020 | |
Baxter Healthcare Corporation | 0338-0210 | INTRAVENOUS | 400 mg in 100 mL | 9/21/2020 | |
Baxter Healthcare Corporation | 0338-1089 | INTRAVENOUS | 213 mg in 100 mL | 4/13/2021 | |
Baxter Healthcare Corporation | 0338-1099 | INTRAVENOUS | 250 mg in 100 mL | 4/13/2021 | |
ICU Medical Inc. | 0990-7171 | INTRAVENOUS | 795 mg in 100 mL | 5/4/2022 | |
Baxter Healthcare Corporation | 0338-0194 | INTRAVENOUS | 400 mg in 100 mL | 4/13/2021 | |
Baxter Healthcare Company | 0338-1147 | INTRAVENOUS | 250 mg in 100 mL | 9/21/2020 | |
Baxter Healthcare Corporation | 0338-1147 | INTRAVENOUS | 250 mg in 100 mL | 9/21/2020 | |
Baxter Healthcare Company | 0338-1142 | INTRAVENOUS | 138 mg in 100 mL | 9/21/2020 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
VAMINOLACT INTRAVENOUS SOLUTION | SIN07428P | INJECTION | 3.8 g/1000 ml | 5/12/1993 | |
AMINOVEN SOLUTION FOR INFUSION 10% | SIN11829P | INJECTION | 6.500 g/1000 ml | 2/28/2002 | |
PRIMENE 10% AMINO ACID INTRAVENOUS INFUSION | SIN10252P | INJECTION | 4 g/l | 9/23/1998 | |
AMINOSTERIL N-HEPA FOR INTRAVENOUS INFUSION 8% | SIN10000P | INJECTION | 2.24 g/l | 9/15/1998 | |
SmofKabiven Emulsion for Infusion | SIN14286P | INJECTION, EMULSION | 6.5g /1000ml | 1/8/2013 | |
KABIVEN PERIPHERAL EMULSION FOR INFUSION | SIN11718P | INJECTION | 0.94 g/l | 11/16/2001 | |
NUTRIFLEX® OMEGA PLUS EMULSION FOR INFUSION | SIN15468P | INJECTION, EMULSION | 2.880g/1000ml | 4/23/2018 | |
PERIOLIMEL N4E Emulsion for Infusion | SIN16888P | EMULSION | 1.00g/L | 10/20/2023 | |
TROPHAMINE INJECTION 10% | SIN07846P | INJECTION | 0.38 g/100 ml | 9/12/1994 | |
AMINOPLASMAL B.BRAUN 10% E SOLUTION FOR INFUSION | SIN15411P | INFUSION, SOLUTION | 2.30g/1000ml | 1/23/2018 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
VAMINOLACT I.V. SOLUTION | N/A | N/A | N/A | 10/14/1992 | |
OLIMEL N9E EMULSION FOR INFUSION | N/A | N/A | N/A | 10/24/2013 | |
NUTRIFLEX OMEGA SPECIAL EMULSION FOR INFUSION | N/A | N/A | N/A | 1/11/2012 | |
NUTRIFLEX OMEGA PLUS EMULSION FOR INFUSION | N/A | N/A | N/A | 1/11/2012 | |
NUTRINEAL PD-4 W/1.1% AA PERITONEAL DIAL SOLN | N/A | N/A | N/A | 12/31/2003 | |
NUTRINEAL PD4 SOLUTION | N/A | N/A | N/A | 9/9/1999 |
TGA Drug Approvals
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
4.25% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTRLYTES IN 10% DEXTROSE | baxter corporation clintec nutrition division | N/A | Solution - Intravenous | 212.5 MG / 100 ML | 12/31/1996 |
4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE | baxter corporation clintec nutrition division | N/A | Solution - Intravenous | 212.5 MG / 100 ML | 12/31/1996 |
2.75%TRAVASOL AMINO ACID INJ.W.ELEC.W.5%DEX. | clintec nutrition company | 02143240 | Liquid - Intravenous | 137.5 MG / 100 ML | 12/31/1996 |
4.25%TRAVASOL AMINO ACID INJ.W.ELECW.5%DEX. | clintec nutrition company | 02143224 | Liquid - Intravenous | 212.5 MG / 100 ML | 12/31/1996 |
5% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 25% DEXTROSE | baxter corporation clintec nutrition division | 02142244 | Solution - Intravenous | 250 MG / 100 ML | 12/31/1996 |
5% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 20% DEXTROSE | baxter corporation clintec nutrition division | 02142252 | Solution - Intravenous | 250 MG / 100 ML | 12/31/1996 |
5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 20% DEXTROSE | baxter corporation clintec nutrition division | 02142368 | Solution - Intravenous | 250 MG / 100 ML | 12/31/1996 |
4.25% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 25% DEXTROSE | baxter corporation clintec nutrition division | 02142295 | Solution - Intravenous | 212.5 MG / 100 ML | 12/31/1996 |
OLIMEL 5.7% E | baxter corporation | 02352532 | Emulsion - Intravenous | 2.25 G / L | 1/19/2011 |
AMINOSYN 8.5% | hospira healthcare ulc | 00613320 | Solution - Intravenous | 370 MG / 100 ML | 12/31/1984 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
NEPHROTECT SOLUCION PARA PERFUSION | 67038 | SOLUCIÓN PARA PERFUSIÓN | Uso Hospitalario | Commercialized | |
SMOFKABIVEN PERIFERICO EMULSION PARA PERFUSION | Fresenius Kabi España, S.A.U. | 70513 | EMULSIÓN PARA PERFUSIÓN | Uso Hospitalario | Commercialized |
PEDIAVEN G20 SOLUCION PARA PERFUSION | Fresenius Kabi España, S.A.U. | 78951 | SOLUCIÓN PARA PERFUSIÓN | Uso Hospitalario | Not Commercialized |
AMINOVEN INFANT 10% SOLUCION PARA PERFUSION | Fresenius Kabi España, S.A.U. | 59628 | SOLUCIÓN PARA PERFUSIÓN | Uso Hospitalario | Commercialized |
SMOFKABIVEN EXTRA NITROGEN EMULSION PARA PERFUSION | Fresenius Kabi España, S.A.U. | 82509 | EMULSIÓN PARA PERFUSIÓN | Uso Hospitalario | Commercialized |
SMOFKABIVEN SIN ELECTROLITOS CENTRAL EMULSION PARA PERFUSION | Fresenius Kabi España, S.A.U. | 70892 | EMULSIÓN PARA PERFUSIÓN | Uso Hospitalario | Commercialized |
OMEGAFLEX ESPECIAL EMULSION PARA PERFUSION | 82104 | EMULSIÓN PARA PERFUSIÓN | Uso Hospitalario | Commercialized | |
LIPOFLEX SPECIAL SIN ELECTROLITOS EMULSION PARA PERFUSION EFG | 82266 | EMULSIÓN PARA PERFUSIÓN | Uso Hospitalario | Commercialized | |
SYNTHAMIN 17 REFORMULADO SOLUCION PARA PERFUSION | Baxter S.L. | 58196 | SOLUCIÓN PARA PERFUSIÓN | Uso Hospitalario | Commercialized |
AMINOPLASMAL PAED 10% SOLUCION PARA PERFUSION | 78871 | SOLUCIÓN PARA PERFUSIÓN | Uso Hospitalario | Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.